Standard

TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors. / Alsalloum, Alaa; Alrhmoun, Saleh; Shevchenko, Julia et al.

In: Biomedicines, Vol. 11, No. 10, 2805, 16.10.2023.

Research output: Contribution to journalArticlepeer-review

Harvard

Alsalloum, A, Alrhmoun, S, Shevchenko, J, Fisher, M, Philippova, J, Perik-Zavodskii, R, Perik-Zavodskaia, O, Lopatnikova, J, Kurilin, V, Volynets, M, Akahori, Y, Shiku, H, Silkov, A & Sennikov, S 2023, 'TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors', Biomedicines, vol. 11, no. 10, 2805. https://doi.org/10.3390/biomedicines11102805

APA

Alsalloum, A., Alrhmoun, S., Shevchenko, J., Fisher, M., Philippova, J., Perik-Zavodskii, R., Perik-Zavodskaia, O., Lopatnikova, J., Kurilin, V., Volynets, M., Akahori, Y., Shiku, H., Silkov, A., & Sennikov, S. (2023). TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors. Biomedicines, 11(10), [2805]. https://doi.org/10.3390/biomedicines11102805

Vancouver

Alsalloum A, Alrhmoun S, Shevchenko J, Fisher M, Philippova J, Perik-Zavodskii R et al. TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors. Biomedicines. 2023 Oct 16;11(10):2805. doi: 10.3390/biomedicines11102805

Author

Alsalloum, Alaa ; Alrhmoun, Saleh ; Shevchenko, Julia et al. / TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors. In: Biomedicines. 2023 ; Vol. 11, No. 10.

BibTeX

@article{ad55a7fc2b66413ab157d768eeeb502f,
title = "TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors",
abstract = "Adoptive T-cell therapies tailored for the treatment of solid tumors encounter intricate challenges, necessitating the meticulous selection of specific target antigens and the engineering of highly specific T-cell receptors (TCRs). This study delves into the cytotoxicity and functional characteristics of in vitro-cultured T-lymphocytes, equipped with a TCR designed to precisely target the cancer-testis antigen NY-ESO-1. Flow cytometry analysis unveiled a notable increase in the population of cells expressing activation markers upon encountering the NY-ESO-1-positive tumor cell line, SK-Mel-37. Employing the NanoString platform, immune transcriptome profiling revealed the upregulation of genes enriched in Gene Ontology Biological Processes associated with the IFN-γ signaling pathway, regulation of T-cell activation, and proliferation. Furthermore, the modified T cells exhibited robust cytotoxicity in an antigen-dependent manner, as confirmed by the LDH assay results. Multiplex immunoassays, including LEGENDplex{\texttrademark}, additionally demonstrated the elevated production of cytotoxicity-associated cytokines driven by granzymes and soluble Fas ligand (sFasL). Our findings underscore the specific targeting potential of engineered TCR T cells against NY-ESO-1-positive tumors. Further comprehensive in vivo investigations are essential to thoroughly validate these results and effectively harness the intrinsic potential of genetically engineered T cells for combating cancer.",
author = "Alaa Alsalloum and Saleh Alrhmoun and Julia Shevchenko and Marina Fisher and Julia Philippova and Roman Perik-Zavodskii and Olga Perik-Zavodskaia and Julia Lopatnikova and Vasily Kurilin and Marina Volynets and Yasushi Akahori and Hiroshi Shiku and Alexander Silkov and Sergey Sennikov",
note = "This work was carried out with the support of the Russian Science Foundation, project number 21-65-00004 (https://rscf.ru/en/project/21-65-00004/, accessed on 20 April 2021).",
year = "2023",
month = oct,
day = "16",
doi = "10.3390/biomedicines11102805",
language = "English",
volume = "11",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "10",

}

RIS

TY - JOUR

T1 - TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors

AU - Alsalloum, Alaa

AU - Alrhmoun, Saleh

AU - Shevchenko, Julia

AU - Fisher, Marina

AU - Philippova, Julia

AU - Perik-Zavodskii, Roman

AU - Perik-Zavodskaia, Olga

AU - Lopatnikova, Julia

AU - Kurilin, Vasily

AU - Volynets, Marina

AU - Akahori, Yasushi

AU - Shiku, Hiroshi

AU - Silkov, Alexander

AU - Sennikov, Sergey

N1 - This work was carried out with the support of the Russian Science Foundation, project number 21-65-00004 (https://rscf.ru/en/project/21-65-00004/, accessed on 20 April 2021).

PY - 2023/10/16

Y1 - 2023/10/16

N2 - Adoptive T-cell therapies tailored for the treatment of solid tumors encounter intricate challenges, necessitating the meticulous selection of specific target antigens and the engineering of highly specific T-cell receptors (TCRs). This study delves into the cytotoxicity and functional characteristics of in vitro-cultured T-lymphocytes, equipped with a TCR designed to precisely target the cancer-testis antigen NY-ESO-1. Flow cytometry analysis unveiled a notable increase in the population of cells expressing activation markers upon encountering the NY-ESO-1-positive tumor cell line, SK-Mel-37. Employing the NanoString platform, immune transcriptome profiling revealed the upregulation of genes enriched in Gene Ontology Biological Processes associated with the IFN-γ signaling pathway, regulation of T-cell activation, and proliferation. Furthermore, the modified T cells exhibited robust cytotoxicity in an antigen-dependent manner, as confirmed by the LDH assay results. Multiplex immunoassays, including LEGENDplex™, additionally demonstrated the elevated production of cytotoxicity-associated cytokines driven by granzymes and soluble Fas ligand (sFasL). Our findings underscore the specific targeting potential of engineered TCR T cells against NY-ESO-1-positive tumors. Further comprehensive in vivo investigations are essential to thoroughly validate these results and effectively harness the intrinsic potential of genetically engineered T cells for combating cancer.

AB - Adoptive T-cell therapies tailored for the treatment of solid tumors encounter intricate challenges, necessitating the meticulous selection of specific target antigens and the engineering of highly specific T-cell receptors (TCRs). This study delves into the cytotoxicity and functional characteristics of in vitro-cultured T-lymphocytes, equipped with a TCR designed to precisely target the cancer-testis antigen NY-ESO-1. Flow cytometry analysis unveiled a notable increase in the population of cells expressing activation markers upon encountering the NY-ESO-1-positive tumor cell line, SK-Mel-37. Employing the NanoString platform, immune transcriptome profiling revealed the upregulation of genes enriched in Gene Ontology Biological Processes associated with the IFN-γ signaling pathway, regulation of T-cell activation, and proliferation. Furthermore, the modified T cells exhibited robust cytotoxicity in an antigen-dependent manner, as confirmed by the LDH assay results. Multiplex immunoassays, including LEGENDplex™, additionally demonstrated the elevated production of cytotoxicity-associated cytokines driven by granzymes and soluble Fas ligand (sFasL). Our findings underscore the specific targeting potential of engineered TCR T cells against NY-ESO-1-positive tumors. Further comprehensive in vivo investigations are essential to thoroughly validate these results and effectively harness the intrinsic potential of genetically engineered T cells for combating cancer.

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85175485012&origin=inward&txGid=f1a7146cbe49f80badd471195c73075a

U2 - 10.3390/biomedicines11102805

DO - 10.3390/biomedicines11102805

M3 - Article

C2 - 37893178

VL - 11

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 10

M1 - 2805

ER -

ID: 57517261